PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability. Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
Coronary artery calcium may have a role in stratifying short-term risk in patients with familial hypercholesterolaemia (FH, inherited high cholesterol), according to a new study. This noninvasive approach may have value in targeting treatment with a PCSK9 inhibitor to those patients at highest risk. Read the report
VIDEO: Is coronary artery calcium a risk assessment too in FH? Watch the video
PCSK9 Forum Editor Professor Professor Henry Ginsberg (Columbia University, New York, USA) discusses how the new guidelines might be viewed as a remake of the great spaghetti western called “The Good, the Bad, and the Ugly.” Read the report
PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. The PCSK9 Education and Research Forum is focused on raising awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target. As part of its remit, PCSK9 Education and Research Forum offers healthcare professionals open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; as well as an extensive library of accredited educational materials tailored to the differing needs of registrants.
Our Partnership and Outreach
Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum builds on educational partnerships with such organisations through jointly sponsored symposia, as well as accredited research and educational programmes.